A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

Published on Feb 1, 2015in Arthritis & Rheumatism9.586
· DOI :10.1002/ART.38949
Roy Fleischmann81
Estimated H-index: 81
(UTSW: University of Texas Southwestern Medical Center),
Nemanja Damjanov35
Estimated H-index: 35
(University of Belgrade)
+ 3 AuthorsN. Kinnman6
Estimated H-index: 6
Objective To assess the efficacy and safety of oral decernotinib (VX-509; Vertex Pharmaceuticals) monotherapy in a 12-week, randomized, double-blind, placebo-controlled, dose-ranging study of patients with rheumatoid arthritis (RA). Methods Two hundred four adults with active RA who had been unsuccessfully treated with ≥1 disease-modifying antirheumatic drug were administered placebo tablets or decernotinib twice a day at dosages of 25 mg, 50 mg, 100 mg, or 150 mg. Primary measures of efficacy at week 12 were the response rate according to the American College of Rheumatology 20% improvement criteria (ACR20) and mean change from baseline in the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP). Results At week 12, the ACR20 response rates were 39.0%, 61.0%, 65.0%, and 65.9% in the 25-mg, 50-mg, 100-mg, and 150-mg groups, respectively, and were significantly higher in the 50-mg group (P = 0.007) and the 100-mg and 150-mg groups (P = 0.002) as compared to the response rates in the placebo group (29.3%). The mean change from baseline in DAS28-CRP was greater in the 50-mg, 100-mg, and 150-mg groups as compared to the placebo group (P < 0.001). Decernotinib treatment resulted in higher ACR50 and ACR70 response rates, more patients with DAS28-CRP scores <2.6, and improvements in the Health Assessment Questionnaire disability index as compared to placebo. The most common adverse events in any decernotinib group were nausea (6.1%), headache (4.3%), an increase in levels of alanine aminotransferase (4.3%), and hypercholesterolemia (3.7%). In the groups receiving decernotinib, there was an increased risk of infections and increased liver transaminase levels. Conclusion Decernotinib was efficacious in improving clinical signs and symptoms of RA at week 12 at dosages of 50–150 mg twice a day. Infections and increases in liver transaminase and lipid levels were noted as potential safety signals.
📖 Papers frequently viewed together
#1John J. O'Shea (NIH: National Institutes of Health)H-Index: 137
#2Apostolos Kontzias (NIH: National Institutes of Health)H-Index: 5
Last. Arian Laurence (NIH: National Institutes of Health)H-Index: 60
view all 5 authors...
Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases or Jaks are critical for a large family of cytokines and the first Jak inhibitors has been approved by the FDA. It is therefore timely to conside...
#1Gerd R Burmester (Charité)H-Index: 95
#2Ricardo BlancoH-Index: 61
Last. Charles A Mebus (Pfizer)H-Index: 11
view all 14 authors...
Summary Background Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic agent has been identified which is universally and persistently effective in all patients. We investigated the effectiveness of tofacitinib (CP-690,550), a novel oral Janus kinase inhibitor, as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis. Methods We did a 6-month, double-blind, parallel-group phase 3 study at 82 centres in 13 countries, including North America, Eur...
#1Vasileios C. Kyttaris (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 38
The outlook for patients with rheumatoid arthritis has improved significantly over the last three decades with the use of disease-modifying antirheumatic drugs. However, despite the use of methotrexate, cytokine inhibitors, and molecules targeting T and B cells, a percentage of patients do not respond or lose their response over time. The autoimmune process in rheumatoid arthritis depends on activation of immune cells, which utilize intracellular kinases to respond to external stimuli such as cy...
At month 3, a higher percentage of patients in the tofacitinib groups than in the placebo groups met the criteria for an ACR 20 response (59.8% in the 5-mg tofacitinib group and 65.7% in the 10-mg tofacitinib group vs. 26.7% in the combined placebo groups, P<0.001 for both comparisons). The reductions from baseline in HAQ-DI scores were greater in the 5-mg and 10-mg tofacitinib groups than in the placebo groups (−0.50 and −0.57 points, respectively, vs. −0.19 points; P<0.001). The percentage of ...
#1Ronald F van Vollenhoven (KI: Karolinska Institutet)H-Index: 81
#2Roy FleischmannH-Index: 81
Last. Bethanie WilkinsonH-Index: 16
view all 14 authors...
Background Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated for the treatment of rheumatoid arthritis. Methods In this 12-month, phase 3 trial, 717 patients who were receiving stable doses of methotrexate were randomly assigned to 5 mg of tofacitinib twice daily, 10 mg of tofacitinib twice daily, 40 mg of adalimumab once every 2 weeks, or placebo. At month 3, patients in the placebo group who did not have a 20% reduction from baseline in the number of sw...
#1Edward C. Keystone (Radboud University Nijmegen)H-Index: 1
#2Josef Smolen (Radboud University Nijmegen)H-Index: 1
Last. Piet L. C. M. van Riel (Radboud University Nijmegen)H-Index: 75
view all 3 authors...
RA is defined by the interrelated triad of disease activity, joint damage and disability. Although disease activity and its associated disability are reversible, joint damage and its associated disability are not. Thus, an important goal of RA therapy is to maximally reduce disease activity and thereby mitigate the accumulation of irreversible joint damage. Treatment for patients with RA should be initiated early and aggressively, with frequent assessments and a goal of achieving remission as qu...
#1Yoshiya Tanaka (University of Occupational and Environmental Health Japan)H-Index: 93
#2Y. Maeshima (University of Occupational and Environmental Health Japan)H-Index: 1
Last. Kunihiro YamaokaH-Index: 25
view all 3 authors...
Multiple cytokines play a pivotal role in the pathogenesis of rheumatoid arthritis (RA). The appropriate intracellular signalling pathways must be activated via cytokine receptors on the cell surface, and the tyrosine kinases transduce the first ‘outside to in’ signals to be phosphorylated after receptor binding to its ligand. Among them, members of the Janus kinase (JAK) family are essential for the signalling pathways of various cytokines and are implicated in the pathogenesis of RA. The in vi...
#1Roy Fleischmann (UTSW: University of Texas Southwestern Medical Center)H-Index: 81
#2Maurizio Cutolo (UniGe: University of Genoa)H-Index: 101
Last. Samuel H. Zwillich (Pfizer)H-Index: 31
view all 12 authors...
Objective To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease-modifying antirheumatic drugs. Methods In this 24-week, double-blind, phase IIb study, patients with RA (n = 384) were randomized to receive placebo, tofacitinib at 1, 3, 5, 10, or 15 mg administered orally twice a day, or adalimumab at 40 mg injected ...
Objectives To review the evidence for the efficacy and safety of biological agents in patients with rheumatoid arthritis (RA) to provide data to develop treatment recommendations by the European League Against Rheumatism (EULAR) Task Force. Methods Medline, Embase and Cochrane databases were searched for relevant articles on infliximab (IFX), etanercept (ETN), adalimumab (ADA), certolizumab-pegol (CZP), golimumab (GLM), anakinra (ANA), abatacept (ABT), rituximab (RTX) and tocilizumab (TCZ) publi...
#1Joel M. Kremer (Albany Medical College)H-Index: 89
#2Bradley J. Bloom (Pfizer)H-Index: 3
Last. Samuel H. Zwillich (Pfizer)H-Index: 31
view all 11 authors...
Objective To determine the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response. Methods Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550, 15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 weeks, and were followed up for an additional 6 weeks afte...
Cited By77
#1Yoon-Kyoung Sung (Hanyang University)H-Index: 20
#2Yusun Lee (KU: Korea University)H-Index: 13
An assessment of the relative efficacy and tolerability of tofacitinib, baricitinib, upadacitinib, and filgotinib compared to those of methotrexate (MTX) was performed in disease-modifying antirheumatic drug (DMARD)-naive patients with rheumatoid arthritis (RA). We performed a Bayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) so as to examine the efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib, and MTX in DMA...
#1George E Fragoulis (Glas.: University of Glasgow)H-Index: 16
#2James Brock (Glas.: University of Glasgow)
Last. Stefan Siebert (Glas.: University of Glasgow)H-Index: 26
view all 5 authors...
Abstract null null JAK inhibitors (JAKi) are a new class of targeted therapy that have entered clinical practice for the treatment of immune-mediated rheumatic conditions. JAKi can block the signalling activity of a variety of pro-inflammatory cytokines and therefore have the potential to mediate therapeutic benefits across a wide range of immune-mediated conditions. Several JAKi are licensed and many more undergoing clinical trials. Here we provide a narrative review of the current and upcoming...
#1Ling ZhangH-Index: 1
#2Yihang ZhangH-Index: 1
Last. Jihong PanH-Index: 1
view all 3 authors...
#1Donal P. McLornan (Guy's and St Thomas' NHS Foundation Trust)H-Index: 24
#2Janet E. Pope (UWO: University of Western Ontario)H-Index: 82
Last. Claire N. Harrison (Guy's and St Thomas' NHS Foundation Trust)H-Index: 74
view all 0 authors...
Summary null An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signalling in multiple disease states has led to an increasing applicability of therapeutic intervention with JAK inhibitors. These agents have revolutionised treatments for a heterogeneous group of disorders, such as myeloproliferative neoplasms, rheumatoid arthritis, inflammatory bowel disease, and multiple immune-driven dermatological diseases, exemplifyin...
#1Jawad Bilal (UA: University of Arizona)H-Index: 7
#2Irbaz Bin Riaz (Mayo Clinic)H-Index: 22
Last. C. Kent Kwoh (UA: University of Arizona)H-Index: 58
view all 14 authors...
Abstract Objective To assess the risk of venous thromboembolism (VTE) in patients treated with Janus kinase (JAK) inhibitors in clinical trials. Patients and Methods We performed a literature search of Ovid MEDLINE and ePub Ahead of Print, In-Process & Other Non-Indexed Citations, and Daily; Ovid EMBASE; Ovid Cochrane Central Register of Controlled Trials; Ovid Cochrane Database of Systematic Reviews; and Scopus, from inception to December 4, 2019, for randomized, placebo-controlled trials with ...
#1Christine Liu (NIH: National Institutes of Health)H-Index: 4
#2Jacqueline Kieltyka (NIH: National Institutes of Health)H-Index: 3
Last. John J. O'Shea (NIH: National Institutes of Health)H-Index: 137
view all 5 authors...
The discovery of cytokines and their role in immune and inflammatory disease led to the development a plethora of targeted biologic therapies. Later, efforts to understand mechanisms of cytokine signal transduction led to the discovery of Janus kinases (JAKs), which themselves were quickly identified as therapeutic targets. It has been a decade since the first JAK inhibitors (jakinibs) were approved and now there are nine jakinibs approved for treatment of rheumatologic, dermatologic, hematologi...
#1Claudia Monfroni Rocha (Univates)H-Index: 1
#2Alessandro Menna Alves (Univates)H-Index: 3
Last. Márcia Inês Goettert (Univates)H-Index: 15
view all 7 authors...
OBJECTIVE One-third of patients with severe rheumatoid arthritis (RA) do not achieve remission or low disease activity, or they have side effects from cDMARD and bDMARD. They will need a new treatment option such as the small molecule JAK inhibitors. In this systematic review, we evaluate the efficacy and safety data of the current jakinibs: tofacitinib, peficitinib, decernotinib, upadacitinib, baricitinib and filgotinib in patients in whom treatment with conventional or biological disease-modif...
#7Jian Wu (Soochow University (Suzhou))H-Index: 95
Objectives To assess the efficacy and safety of jakinibs for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response or intolerance to conventional synthetic or biologic disease-modifying antirheumatic drugs (DMARDs). Methods A systematic search was conducted in PubMed, Embase, and the Cochrane Library. Randomized placebo-controlled trials (RCTs) of jakinibs in RA patients were eligible. The effective outcome was RA improvement to reach an American College of Rh...
In an earlier publication a binary model for chronic diseases classification has been proposed. According to the model, chronic diseases were classified as "high Treg" or "low Treg" diseases, depending on whether the immune response is anti- or pro-inflammatory and assuming that regulatory T cells are major determinants of the response. It turned out that most cancers are "high Treg" diseases, while autoimmune diseases are "low Treg". This paper proposes a molecular cause for this binary respons...
#1Rita A Moura (IMM: Instituto de Medicina Molecular)H-Index: 11
#2João Eurico Fonseca (IMM: Instituto de Medicina Molecular)H-Index: 48
Rheumatoid arthritis (RA) is a chronic, systemic immune-mediated inflammatory disease that can lead to joint destruction, functional disability and substantial comorbidity due to the involvement of multiple organs and systems. B cells have several important roles in RA pathogenesis, namely through autoantibody production, antigen presentation, T cell activation, cytokine release and ectopic lymphoid neogenesis. The success of B cell depletion therapy with rituximab, a monoclonal antibody directe...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.